Vir Biotechnology, Inc. - Common Stock (VIR)

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

The company is working to engage the immune system to attack cancer cells.

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.

Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.

These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.

Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.

VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.

These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.